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1. INTRODUCTION {#coa13239-sec-0007}
===============

Surgical resection is the primary treatment modality of oral squamous cell carcinoma (OSCC). The decision whether to apply postoperative radiotherapy (PORT) depends on the risk of local or locoregional recurrence (LR).[1](#coa13239-bib-0001){ref-type="ref"}, [2](#coa13239-bib-0002){ref-type="ref"}, [3](#coa13239-bib-0003){ref-type="ref"}, [4](#coa13239-bib-0004){ref-type="ref"} To improve local control in advanced disease (stage III‐IV), surgical resection is followed by PORT. In early‐stage tumours (I‐II), there is often no indication for radiotherapy. However, PORT should be given to cases with high risk of recurrence such as positive surgical margins (\<1 mm), multiple affected lymph nodes (N ≥ 2b) and extracapsular extension, in order to improve locoregional control.[5](#coa13239-bib-0005){ref-type="ref"} It is not entirely clear in intermediate risk cases of early‐stage OSCC with close margins (1‐5 mm), poor differentiation, pT3‐4, lymphangio invasion and perineural invasion (PNI), as to when PORT should be applied.[5](#coa13239-bib-0005){ref-type="ref"} There is a need for research regarding adjuvant radiotherapy in intermediate risk cases, which was also pointed out by Blackburn et al.[6](#coa13239-bib-0006){ref-type="ref"}

The risk of LR in the presence of PNI is unclear.[2](#coa13239-bib-0002){ref-type="ref"}, [7](#coa13239-bib-0007){ref-type="ref"}, [8](#coa13239-bib-0008){ref-type="ref"}, [9](#coa13239-bib-0009){ref-type="ref"}, [10](#coa13239-bib-0010){ref-type="ref"} Some studies found a significant increase in LR rates in PNI cases,[10](#coa13239-bib-0010){ref-type="ref"}, [11](#coa13239-bib-0011){ref-type="ref"}, [12](#coa13239-bib-0012){ref-type="ref"} while other studies did not.[13](#coa13239-bib-0013){ref-type="ref"}, [14](#coa13239-bib-0014){ref-type="ref"} Moreover, it is not clear whether PORT has an additional, positive effect in reducing the local recurrence rate in early OSCC with PNI. Evidence regarding prognosis is needed to justify the role of PORT, because of its side effects such as xerostomia, dysphagia, loss of taste, trismus and osteoradionecrosis.[15](#coa13239-bib-0015){ref-type="ref"}, [16](#coa13239-bib-0016){ref-type="ref"}, [17](#coa13239-bib-0017){ref-type="ref"}

The objectives of this study were to systematically review the literature to find whether PNI in OSCC patients is associated with a higher LR rate and whether LR rate is influenced by administration of PORT in OSCC patients presenting with PNI.

2. METHODS {#coa13239-sec-0008}
==========

2.1. Study identification and selection {#coa13239-sec-0009}
---------------------------------------

The study protocol was designed using the PRISMA statement for reporting systematic reviews and meta‐analyses.[18](#coa13239-bib-0018){ref-type="ref"} A search protocol was developed prior to the study. Studies were sought in electronic databases namely, PubMed, Embase and Web of Science. The last search date was 18 September 2017. No limitations were applied regarding time of study or study design. Only studies written in English were included. A general search strategy was developed together with an information specialist and adapted appropriately to each database (Appendix [1](#coa13239-app-0001){ref-type="app"}). Publications were included if they described: the treatment of patients with squamous cell carcinoma of the oral cavity; PNI; local recurrence; whether PORT was given or not; and a sample size of ≥10. Local recurrence was defined as histopathologically proven tumour arising within 10 mm from the primary tumour. Publications were excluded if brachytherapy was given, if preoperative radiotherapy or other earlier treatments were provided, if recurrent or secondary tumours were included, if pathological T‐stage was not reported or if the intent of treatment was not curative.

First, titles were assessed for selection by two observers independently (JV and KS). Abstracts from the included titles were then assessed by the same observers. Titles with insufficient information or causing disagreement between the observers were also included for abstract assessment. If an abstract provided insufficient information or disagreement existed between observers, the text was checked. Thereafter, full‐text papers were assessed in a similar way. Finally, the references of the included studies were also perused for inclusion and if any were selected, the same procedure was followed as described above. Studies in which only a part of the study group met the inclusion criteria were included for further analysis of the relevant group. Interobserver agreement was expressed as Cohen\'s κ and as a percentage of agreement.

In cases of disagreement about inclusion or exclusion, a decision was made by consensus. A third reviewer (MJHW) was consulted to resolve remaining disagreements.

2.2. Data extraction {#coa13239-sec-0010}
--------------------

The relevant data of the included papers were extracted onto a standardised form by the first author (JV) according to the following categories: dates over which the study was conducted; patient characteristics; tumour characteristics (including location in the oral cavity, T‐stage and histopathologic factors); adjuvant (chemo)radiotherapy (including chemotherapy agent and dosing, technique of radiotherapy and dose and fractionation of the radiation); and local recurrence (in relation to PNI and adjuvant radiotherapy). All data extraction was verified by another reviewer (PUD).

2.3. Study quality assessment {#coa13239-sec-0011}
-----------------------------

The quality of the included studies was assessed based on the "Newcastle‐Ottawa Scale (NOS) for assessing the Quality of Nonrandomized Studies"[19](#coa13239-bib-0019){ref-type="ref"} by the first author. These included the study groups, comparability of the groups and ascertainment of outcome of interest. The NOS can be found in Appendix [2](#coa13239-app-0002){ref-type="app"}.

3. RESULTS {#coa13239-sec-0012}
==========

3.1. Study selection {#coa13239-sec-0013}
--------------------

The searches in PubMed, Embase and Web of Science yielded 976, 1755 and 63 hits, respectively (Figure [1](#coa13239-fig-0001){ref-type="fig"}). After deduplication, 2085 papers remained. The interobserver agreement for title and abstract selection was 0.73 (SE = 0.029), and absolute agreement was 95.7%. Following title and abstract selection, 119 papers remained for full‐text assessment (interobserver agreement 0.61 (SE = 0.089), absolute agreement 97.5%) after which a total of 13 studies were potentially eligible for inclusion in this systematic review. A reference check did not result in additional relevant studies. Six of the 13 studies were excluded because of insufficient data or irrelevant comparisons. Qualitative data analysis was performed on the remaining seven studies. Data synthesis was not performed because of the heterogeneity of the study designs and populations.

![Flow chart of the selection process](COA-44-131-g001){#coa13239-fig-0001}

3.2. Characteristics of included studies {#coa13239-sec-0014}
----------------------------------------

All studies were retrospective cohorts published between 2011 and 2016. Sample size ranged from 78 to 442 patients (Table [1](#coa13239-tbl-0001){ref-type="table"}). All the studies included primary tumours of the oral cavity with surgery as a primary treatment. The definition of PNI differed between the studies. The most used definition of PNI was the presence of tumour cells in any of the three layers of the nerve sheath and/or tumour cells in close proximity to the nerve involving more than one‐third of its circumference.[1](#coa13239-bib-0001){ref-type="ref"}, [8](#coa13239-bib-0008){ref-type="ref"}, [20](#coa13239-bib-0020){ref-type="ref"} In another study, the definition of PNI was limited to the presence of tumour cells within any of the three layers of the nerve sheath[21](#coa13239-bib-0021){ref-type="ref"} and another three studies did not define PNI at all.[22](#coa13239-bib-0022){ref-type="ref"}, [23](#coa13239-bib-0023){ref-type="ref"} Three studies included patients with all pathological T‐stages,[1](#coa13239-bib-0001){ref-type="ref"}, [21](#coa13239-bib-0021){ref-type="ref"}, [24](#coa13239-bib-0024){ref-type="ref"} whereas four studies included patients solely with pT1‐2 tumors.[22](#coa13239-bib-0022){ref-type="ref"}, [23](#coa13239-bib-0023){ref-type="ref"}, [25](#coa13239-bib-0025){ref-type="ref"} Two studies excluded patients with positive or close resection margins.[1](#coa13239-bib-0001){ref-type="ref"}, [23](#coa13239-bib-0023){ref-type="ref"} All the studies reported the resection margins, but only five studies defined them.[1](#coa13239-bib-0001){ref-type="ref"}, [20](#coa13239-bib-0020){ref-type="ref"}, [23](#coa13239-bib-0023){ref-type="ref"}, [24](#coa13239-bib-0024){ref-type="ref"}, [25](#coa13239-bib-0025){ref-type="ref"} Other histopathologic features were described adequately in five studies.[8](#coa13239-bib-0008){ref-type="ref"}, [20](#coa13239-bib-0020){ref-type="ref"}, [21](#coa13239-bib-0021){ref-type="ref"}, [22](#coa13239-bib-0022){ref-type="ref"}, [25](#coa13239-bib-0025){ref-type="ref"} One study excluded patients with adverse histopathologic factors such as extracapsular spread and lymphangio invasion.[1](#coa13239-bib-0001){ref-type="ref"} In five studies, patients were treated with PORT, but no specific indication regarding PNI was reported.[1](#coa13239-bib-0001){ref-type="ref"}, [8](#coa13239-bib-0008){ref-type="ref"}, [20](#coa13239-bib-0020){ref-type="ref"}, [21](#coa13239-bib-0021){ref-type="ref"}, [23](#coa13239-bib-0023){ref-type="ref"} Of those studies, four reported that PORT[1](#coa13239-bib-0001){ref-type="ref"}, [8](#coa13239-bib-0008){ref-type="ref"}, [20](#coa13239-bib-0020){ref-type="ref"}, [23](#coa13239-bib-0023){ref-type="ref"} was applied to 3.6%‐43.4% of the patients. One study did not report which patients were treated with PORT.[21](#coa13239-bib-0021){ref-type="ref"} Two other studies excluded the patients treated with PORT.[22](#coa13239-bib-0022){ref-type="ref"}, [25](#coa13239-bib-0025){ref-type="ref"} All the studies analysed different variables, but all had local recurrence as either a primary or secondary outcome.

###### 

Study characteristics

  Author, publication year   Tai, 2011[24](#coa13239-bib-0024){ref-type="ref"}   Ganly, 2012[19](#coa13239-bib-0019){ref-type="ref"}   Chen, 2013[20](#coa13239-bib-0020){ref-type="ref"}   Chatzistefanou, 2014[1](#coa13239-bib-0001){ref-type="ref"}   Aivazian, 2015[7](#coa13239-bib-0007){ref-type="ref"}   Matsushita, 2015[18](#coa13239-bib-0018){ref-type="ref"}   Low, 2016[22](#coa13239-bib-0022){ref-type="ref"}
  -------------------------- --------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------
  Country                    Taiwan                                              USA                                                   Taiwan                                               USA                                                           Australia                                               Japan                                                      Australia
  Center                     Taipei Veterans General Hospital                    Multicenter[c](#coa13239-note-0004){ref-type="fn"}    National Taiwan University Hospital                  University of Maryland                                        Royal Prince Alfred Hospital                            Nagasaki University                                        Sydney Head and Neck Cancer Institute
  Design                     RC                                                  RC                                                    RC                                                   RC                                                            RC                                                      RC                                                         RC
  Study period               2001‐2009                                           1985‐2005                                             2004‐2009                                            2005‐2011                                                     1995‐2010                                               2001‐2011                                                  1988‐2013
  Data source                Medical records                                     NR                                                    Medical records &Pathologic reports                  NR                                                            Medical records                                         Medical records                                            NR
  Total sample (n)           307                                                 164                                                   442                                                  78                                                            318                                                     89                                                         121
  Male (n)                   267                                                 90                                                    374                                                  55                                                            194                                                     50                                                         75
  Age (range)                ≤54, n = 172                                        \<60, n = 98                                          ≤50, n = 207                                         \<60, n = 39                                                  64[a](#coa13239-note-0002){ref-type="fn"} (30‐92)       \>63, n = 48                                               61[a](#coa13239-note-0002){ref-type="fn"} (47‐74)
  \>54, n = 135              ≥60, n = 66                                         \>50, n = 235                                         ≥60, n = 39                                          ≤63, n = 41                                                                                                                                                                      
  Follow‐up (mo)             49.1[a](#coa13239-note-0002){ref-type="fn"}         66[a](#coa13239-note-0002){ref-type="fn"}             46[b](#coa13239-note-0003){ref-type="fn"}            42.7[b](#coa13239-note-0003){ref-type="fn"}                   32.4[a](#coa13239-note-0002){ref-type="fn"}             49.4[b](#coa13239-note-0003){ref-type="fn"}                38[a](#coa13239-note-0002){ref-type="fn"}
  Treatment                                                                                                                                                                                                                                                                                                                                                                  
  Surgery                    245                                                 164                                                   426                                                  48                                                            180                                                     NR                                                         121
  Surgery + RT               22                                                  0                                                     16                                                   30                                                            124                                                     NR                                                         0
  Surgery + CRT              40                                                  0                                                     0                                                    0                                                             14                                                      NR                                                         0
  Type of RT (dose)          NR (62.8 Gy PNI + 60 Gy PNI−)                       ---                                                   NR                                                   NR (50‐70 Gy)                                                 NR                                                      NR                                                         ---
  Type of chemotherapy       Cisplatin                                           ---                                                   ---                                                  ---                                                           NR                                                      ---                                                        ---
  NOS rating                 5                                                   5                                                     5                                                    5                                                             8                                                       6                                                          6

CRT, chemoradiotherapy; n, number; NOS, Newcastle‐Ottawa Scale; NR, not reported; RC, retrospective cohort; RT, radiotherapy.

Median.

Mean.

Memorial Sloan‐Kettering Cancer Center (New York, NY) and Princess Margaret Cancer Center (Toronto, Ontario, Canada).

John Wiley & Sons, Ltd

3.3. Local recurrence {#coa13239-sec-0015}
---------------------

None of the seven studies reported PNI as a significant prognostic factor for LR; however, one study reported PNI as a significant prognostic factor if it was presenting multifocally, especially if nerves \>1 mm were involved (*P* = 0.049).[8](#coa13239-bib-0008){ref-type="ref"} None of the seven included studies evaluated the impact of PORT in patients presenting with PNI. A summary of study findings can be found in Table [2](#coa13239-tbl-0002){ref-type="table"}.

###### 

Summary of study findings

  Author, year           Total, n   pT1                                         pT2                                         pT3   pT4   Local recurrence in PNI+ patients              Local recurrence in PNI− patients   HR                                             *P*‐value                                                                                                  
  ---------------------- ---------- ------------------------------------------- ------------------------------------------- ----- ----- ---------------------------------------------- ----------------------------------- ---------------------------------------------- ---------------------------------------------- ----- ------- --------------------------------------------- -------
  Tai, 2011              307        146                                         161                                         ---   ---   84                                             16                                  19.0%                                          223                                            30    13.5%   ---                                           0.221
  Ganly, 2012            164        76                                          88                                          ---   ---   22[b](#coa13239-note-0007){ref-type="fn"}      1                                   4.5%                                           124[b](#coa13239-note-0007){ref-type="fn"}     13    10.5%   ---                                           0.56
  Chen, 2013             442        272                                         170                                         ---   ---   65                                             12                                  18.5%[c](#coa13239-note-0008){ref-type="fn"}   377                                            55    14.6%   ---                                           NS
  Chatzistefanou, 2014   78         50[a](#coa13239-note-0006){ref-type="fn"}   28[a](#coa13239-note-0006){ref-type="fn"}   ---   ---   26.3%[d](#coa13239-note-0009){ref-type="fn"}   ---                                 ---                                            27.5%[d](#coa13239-note-0009){ref-type="fn"}   ---   0.332                                                 
  Aivazian, 2015         318        108                                         106                                         26    76    ---                                            ---                                 ---                                            ---                                            ---   ---     1.26[e](#coa13239-note-0010){ref-type="fn"}   1.00
  Matsushita, 2015       89         82[a](#coa13239-note-0006){ref-type="fn"}   7[a](#coa13239-note-0006){ref-type="fn"}    ---   ---   23%                                            ---                                 ---                                            26%                                            ---   NS                                                    
  Low, 2016              121        121                                         ---                                         ---   ---   24                                             5                                   20.8%                                          65                                             6     9.2%    ---                                           0.33

HR, hazard ratio; LR, local recurrence; n, number; NS, not significant; PNI−, perineural invasion‐negative; PNI+, perineural invasion‐positive.

These numbers represent T1 and T2 or T3 and T4 cases.

There were also a number of patients in which PNI was not reported.

PNI and lymphovascular invasion were combined as a high risk group in the calculations of local recurrence.

Local recurrence rates were calculated in patients who did not receive postoperative radiotherapy.

Hazard ratios were 0.42 (*P* = 0.247) and 2.24 (*P* = 0.049) for unifocal and multifocal, respectively.

John Wiley & Sons, Ltd

4. DISCUSSION {#coa13239-sec-0016}
=============

4.1. Summary of main results {#coa13239-sec-0017}
----------------------------

We used a systematic review to investigate the impact of PNI on LR in OSCC patients and whether LR is influenced by the administration of PORT. Only seven studies could be included, and these papers only partly answered the research questions; therefore, high‐quality evidence regarding the impact of PNI on LR rates in patients with OSCC is lacking. All studies reported that there was no significant difference in LR between patients presenting with and without PNI. However, one study reported that PNI was a significant prognostic factor when it is multifocal, especially if nerves \>1 mm are involved. None of the included studies reported the impact of PORT on LR in patients presenting with PNI.

4.2. Comparison with other reviews {#coa13239-sec-0018}
----------------------------------

An earlier systematic review reported that PNI is not a significant prognostic factor for locoregional recurrence.[26](#coa13239-bib-0026){ref-type="ref"} That systematic review included studies describing squamous cell carcinoma in the complete head and neck area and studies only reporting clinical T‐stage were not excluded. Also, local and regional recurrences were listed as locoregional recurrence irrespective of whether these types of recurrences had other aetiologies. Our aim was to evaluate the impact of PNI on LR more precisely by excluding studies only reporting clinical T‐stage and those only including OSCC. A partially retrospective and partially prospective study reported PNI as an independent predictor of LR if nerves \>1 mm were involved[10](#coa13239-bib-0010){ref-type="ref"}; however, this study was excluded in our study because pathological T‐stage was not described and squamous cell carcinoma of the pharynx was also included. Another study did not find any association between nerve size and LR; however, this might be explained by the fact that only nerves smaller than 1 mm were encountered in that study.[9](#coa13239-bib-0009){ref-type="ref"} The extent of PNI was evaluated by Chinn et al. on attempting to demonstrate an association between the extent of PNI and the size of the nerves involved, but they failed, probably due to the lack of an adequate sample size (n = 20).[7](#coa13239-bib-0007){ref-type="ref"}

4.3. Overall completeness and applicability of evidence {#coa13239-sec-0019}
-------------------------------------------------------

The major limitation of the current literature is the lack of a standardised definition of PNI. Based on the results of the present systematic review, there is a need for a standardised definition of PNI in order to obtain exact numbers of its incidence and to evaluate the association between PNI and prognosis.

Furthermore, the majority of the included studies did not describe the location, size of the involved nerves and the extent of PNI. Aivazian et al[8](#coa13239-bib-0008){ref-type="ref"} reported a clinically significant difference between the prognostic value of unifocal and multifocal PNI, especially combined with invasion of nerves \>1 mm; therefore, it seems it is not enough to only report PNI as absent or present.

Finally, there were no data available on the selection criteria of patients receiving adjuvant treatment because of PNI. Therefore, it remains unclear at which point PORT was administered to the PNI‐positive and the PNI‐negative group and no conclusions can be drawn about the additional effect of PORT on LR.

4.4. Quality of evidence {#coa13239-sec-0020}
------------------------

Although over 2000 papers were identified in the database search, only seven papers could be included in this systematic review. A very common reason for exclusion was the non‐reporting of pathological T‐stage; only clinical T‐stage was reported. Pathological T‐stage is essential to evaluate prognosis. Furthermore, pT1‐2 tumours are clinically most important because an indication for PORT is based on secondary histopathological factors in these early‐stage tumours, whereas most institutes use pT3‐4 tumours as an indication for PORT.[5](#coa13239-bib-0005){ref-type="ref"} Also a considerable number of studies were excluded because locoregional recurrence was reported instead of separate local and regional recurrence. The level of evidence of the included studies was limited because of their retrospective design.

4.5. Implications for research {#coa13239-sec-0021}
------------------------------

In order to determine the indication for PORT, prospective studies need to be performed to investigate the effect of PORT in patients presenting with PNI on LR. It would be important to introduce a standardised definition of PNI to obtain exact incidence rates. Also, the extent of PNI should be described more specifically by means of the location and the size of the involved nerves. Finally, accurate data registration including precise description of the cohort, pathological T‐ and N‐stages, resection margins, local recurrence and other pathological tumour characteristics (such as depth of invasion, pattern of growth and lymphovascular invasion) would be essential in order to evaluate prognosis.

5. CONCLUSION {#coa13239-sec-0022}
=============

Based on the available evidence, it is not clear whether there is an indication for PORT in unifocal PNI; moreover, high‐quality evidence is lacking on the impact of PORT in OSCC patients presenting with PNI.
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PubMed {#coa13239-sec-0024}
======

("Mouth"\[Mesh\] OR "Mouth Neoplasms"\[Mesh\] OR tongue\[tiab\] OR oral\[tiab\] OR mouth\[tiab\] OR gingiva\*\[tiab\])

AND ("Mouth Neoplasms"\[Mesh\] OR OSCC\[tiab\] OR SCC\[tiab\] OR squamous cell\[tiab\] OR cancer\[tiab\] OR carcinoma\*\[tiab\] OR tumour\*\[tiab\] OR tumor\*\[tiab\])

AND ("Radiotherapy, Adjuvant"\[Mesh\] OR "Chemoradiotherapy"\[Mesh\] OR "radiotherapy" \[Subheading\] OR chemoradiother\*\[tiab\] OR chemo radio therap\*\[tiab\] OR radio chemo therap\*\[tiab\] OR radiochemother\*\[tiab\] OR (chemoradio\*\[tiab\] AND therap\*\[tiab\]) OR (radiochemo\*\[tiab\] AND therap\*\[tiab\]) OR radiother\*\[tiab\] OR (radiation\[tiab\] AND (postoperative\[tiab\] OR post‐operative\[tiab\] OR adjuvant\[tiab\])))

AND ("Neoplasm Recurrence, Local"\[Mesh\] OR "Mortality"\[Mesh\] OR "Survival"\[Mesh\] OR recurren\*\[tiab\] OR surviv\*\[tiab\] OR mortality\[tiab\] OR death\*\[tiab\])

AND ("Neoplasm Invasiveness"\[Mesh\] OR Perineural\[tiab\] OR invasi\*\[tiab\] OR characteristic\*\[tiab\] OR agressi\*\[tiab\])

Embase {#coa13239-sec-0025}
======

('Mouth'/exp OR 'mouth cancer'/exp OR 'tongue tumor'/exp OR tongue:ab,ti OR oral:ab,ti OR mouth:ab,ti OR gingiva\*:ab,ti)

AND

('mouth cancer'/exp OR 'tongue tumor'/exp OR oscc:ab,ti OR scc:ab,ti OR 'squamous cell':ab,ti OR cancer:ab,ti OR carcinoma\*:ab,ti OR tumour\*:ab,ti OR tumor\*:ab,ti)

AND

('cancer adjuvant therapy'/exp OR 'cancer radiotherapy'/exp OR chemoradiother\*:ab,ti OR ((chemoradio\* OR radiochemo\*) NEXT/1 therap\*):ab,ti OR radiochemother\*:ab,ti OR radiother\*:ab,ti OR (chemo\* NEAR/3 radio\* NEAR/3 therap\*):ab,ti OR (radiation AND (postoperative OR 'post operative' OR adjuvant)):ab,ti)

AND

('cancer mortality'/exp OR 'cancer recurrence'/exp OR 'cancer survival'/exp OR recurren\*:ab,ti OR surviv\*:ab,ti OR mortality:ab,ti OR death\*:ab,ti)

AND

('tumor invasion'/exp OR perineural:ab,ti OR invasi\*:ab,ti OR characteristic\*:ab,ti OR agressi\*:ab,ti)

Web of Science {#coa13239-sec-0026}
==============

TS=("mouth" OR "tongue" OR gingiva\* OR "oral")

AND

TS=(cancer\* OR tumour\* OR tumor\* OR carcinoma\* OR neoplasm\* OR "scc" OR "oscc" OR "squamous cell")

AND

(TS=(chemo\* NEAR/3 radio\* NEAR/3 therap\*) OR TS=(chemoradio\* OR radiochemo\* OR radiotherap\*) OR TS=("radiation" AND ("postoperative" OR "post operative" OR "adjuvant")))

AND

TS=("mortality" OR surviv\* OR death\* OR recurr\*)

AND

TS=(invas\* OR characteristic\* OR agressi\* OR "perineural")

Newcastle---Ottawa quality assessment scale case control studies {#coa13239-sec-0027}
================================================================

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.

Selection {#coa13239-sec-0028}
---------

1Is the case definition adequate?yes, with independent validation \*yes, eg record linkage or based on self reportsno description2Representativeness of the casesconsecutive or obviously representative series of cases \*potential for selection biases or not stated3Selection of Controlscommunity controls \*hospital controlsno description4Definition of Controlsno history of disease (endpoint) \*no description of source

Comparability {#coa13239-sec-0029}
-------------

Comparability of cases and controls on the basis of the design or analysisstudy controls for\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (Select the most important factor.) \*study controls for any additional factor \* (This criteria could be modified to indicate specific control for a second important factor.)

Exposure {#coa13239-sec-0030}
--------

1Ascertainment of exposuresecure record (eg surgical records) \*structured interview where blind to case/control status \*interview not blinded to case/control statuswritten self report or medical record onlyno description2Same method of ascertainment for cases and controlsyes \*no3Non‐Response ratesame rate for both groups \*non respondents describedrate different and no designation

Newcastle---Ottawa quality assessment scale cohort studies {#coa13239-sec-0031}
==========================================================

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability

Selection {#coa13239-sec-0032}
---------

1Representativeness of the exposed cohorttruly representative of the average \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_(describe) in the community \*somewhat representative of the average \_\_\_\_\_\_\_\_\_\_\_\_\_\_in the community \*selected group of users eg nurses, volunteersno description of the derivation of the cohort2Selection of the non exposed cohortdrawn from the same community as the exposed cohort \*drawn from a different sourceno description of the derivation of the non exposed cohort3Ascertainment of exposuresecure record (eg surgical records) \*structured interview \*written self reportno description4Demonstration that outcome of interest was not present at start of studyyes \*no

Comparability {#coa13239-sec-0033}
-------------

Comparability of cohorts on the basis of the design or analysisstudy controls for \_\_\_\_\_\_\_\_\_\_\_\_\_(select the most important factor) \*study controls for any additional factor \* (This criteria could be modified to indicate specific control for a second important factor.)

Outcome {#coa13239-sec-0034}
-------

1Assessment of outcomeindependent blind assessment \*record linkage \*self reportno description2Was follow‐up long enough for outcomes to occuryes (select an adequate follow up period for outcome of interest) \*no3Adequacy of follow up of cohortscomplete follow up---all subjects accounted for \*subjects lost to follow up unlikely to introduce bias---small number lost ‐ \> \_\_\_\_\_\_\_\_\_\_\_\_\_ % (select an adequate %) follow up, or description provided of those lost) \*follow up rate \<\_\_\_\_\_\_\_\_\_\_\_\_\_% (select an adequate %) and no description of those lostno statement
